FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

仅供研究使用。 完整免责声明 →

肽库

SS-31

Elamipretide / MTP-131 / Bendavia

Longevity & Anti-Aging

SS-31 (Elamipretide, also known as Bendavia or MTP-131) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing cristae structure and optimizing electron transport chain efficiency. Developed by Stealth BioTherapeutics, it represents a novel class of mitochondrial protective agents that do not rely on membrane potential for targeting. Its primary research applications include Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related mitochondrial dysfunction.

作用机制

Mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Binds cardiolipin to optimize electron transport chain function, reduce reactive oxygen species production, and restore mitochondrial bioenergetics.

研究协议

仅供研究使用,非医疗建议。

Clinical trial protocols used 0.25mg/kg/hour IV infusion or 40mg daily subcutaneous injection. Research protocols use 1-5mg daily subcutaneously. Treatment duration varies by indication (4 weeks to 48 weeks in trials).

研究笔记

Clinical Research Status

SS-31 (Elamipretide) has advanced through multiple Phase II and Phase III clinical trials, most notably the TAZPOWER trial for Barth syndrome and the MMPOWER trials for primary mitochondrial myopathy. The FDA granted Fast Track designation for Barth syndrome, though the compound has faced regulatory setbacks with initial NDA submissions requiring additional data. Stealth BioTherapeutics continues clinical development programs targeting heart failure with reduced ejection fraction and dry age-related macular degeneration.

Key Published Findings

In the TAZPOWER Phase II trial, elamipretide demonstrated improvements in 6-minute walk test distance and patient-reported outcomes in Barth syndrome patients over 12 weeks of subcutaneous administration. Preclinical studies have shown SS-31 reduces mitochondrial ROS production by 50-75%, improves ATP synthesis, and prevents cardiolipin peroxidation in ischemia-reperfusion models. Research in aged mice demonstrated that SS-31 treatment reversed age-related declines in skeletal muscle mitochondrial energetics and improved exercise tolerance within one hour of administration.

Safety Profile

SS-31 has demonstrated good tolerability in clinical trials at subcutaneous doses of 4mg and 40mg daily, with injection site reactions being the most common adverse event. Serious adverse events in trials have been infrequent and generally not attributed to the drug. The peptide has a favorable pharmacokinetic profile with rapid absorption, short half-life requiring daily dosing, and no evidence of accumulation or organ toxicity in long-term administration studies.

Drug Interactions & Contraindications

No significant drug-drug interactions have been identified in clinical studies to date, likely due to SS-31's mechanism of action at the mitochondrial membrane rather than via enzymatic pathways. The compound does not appear to interact with cytochrome P450 enzymes or common drug transporters. Caution may be warranted in patients taking other mitochondrial-targeted compounds, though formal interaction studies are limited.

Comparison to Related Compounds

Unlike CoQ10 and MitoQ which require mitochondrial membrane potential for uptake, SS-31 concentrates in mitochondria independent of membrane potential, making it effective even in damaged or dysfunctional mitochondria. MitoQ is a ubiquinone-based antioxidant targeting the matrix, while SS-31 specifically targets the inner membrane cardiolipin interface. SS-31's mechanism of stabilizing cardiolipin microdomains is fundamentally different from traditional antioxidants, addressing structural rather than purely redox-related mitochondrial dysfunction.

Community Observations

Research peptide users report noticeable improvements in exercise capacity and subjective energy levels within the first week of subcutaneous SS-31 administration at 2-5mg daily. The compound has gained significant interest in the longevity community due to preclinical data showing rapid reversal of age-related mitochondrial decline. Users note that SS-31 is relatively expensive and difficult to source compared to other peptides, limiting widespread adoption outside clinical trial settings.

半衰期

~4-6 hours

复溶

Bacteriostatic water (BAC)

存储

冻干

Refrigerate 2-8C. Protect from light.

复溶后

Refrigerate 2-8C. Use within 14 days.

美国法律状态

Research chemical (in clinical trials)

又称作

ElamipretideMTP-131Bendavia

常见问题

什么是 SS-31?

SS-31 (Elamipretide, also known as Bendavia or MTP-131) is a mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane where it binds to cardiolipin, stabilizing cristae structure and optimizing electron transport chain efficiency. Developed by Stealth BioTherapeutics, it represents a novel class of mitochondrial protective agents that do not rely on membrane potential for targeting. Its primary research applications include Barth syndrome, primary mitochondrial myopathy, heart failure, and age-related mitochondrial dysfunction.

SS-31 如何起作用?

Mitochondria-targeted tetrapeptide that selectively concentrates in the inner mitochondrial membrane. Binds cardiolipin to optimize electron transport chain function, reduce reactive oxygen species production, and restore mitochondrial bioenergetics.

SS-31 在美国的监管状态是什么?

Research chemical (in clinical trials)

SS-31 的半衰期是多少?

~4-6 hours

SS-31 还有哪些名称?

Elamipretide, MTP-131, Bendavia

Peptide Contacts仅提供基于研究的摘要,仅供信息参考。我们不托管、分发或支持供应商文档。所有证书分析、GMP证书和供应商通信必须由买家直接请求并验证。本平台上任何内容均不构成法律、医疗或专业建议。用户在购买任何研究化学品之前应自行核实供应商资质,并确保遵守所有适用的当地、州及联邦法律法规,承担全部法律责任。

阅读完整免责声明